Skip to main content
Figure 5 | BMC Immunology

Figure 5

From: A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection

Figure 5

SCH 546738 attenuates disease in mouse collagen-induced arthritis. SCH 546738 in 0.4% methylcellulose was administered orally twice daily at 3, 10 and 40 mg/kg (mpk). Dosing was initiated 16 days (day -4) postimmunization and continued through day 9. The disease score was significantly decreased in SCH 546738-treated animals as compared with vehicle-treated animals (* p < 0.05, two-tailed t test) at day 4, 7 and 9.

Back to article page